References
- Parving H H, Jacobsen P, Rossing K, Smidt U M, Hotnmel E, Rossing P. Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int 1996; 49: 1778–1782
- van den Bom J, van den Heuvel L PWJ, Bakker M AH, Veerkamp J H, Assmann K JM, Berden J HM. A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int 1992; 41: 115–123
- Tamsma J T, van den Bom J, Bruijn J A, Assmann K JM, Weening J J, Berden J HM, Wieslander J, Schrama E, Hermans J, Veerkamp J H, Lemkes H HPJ, van der Woude F J. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glornerular basement membrane. Diabetologia 1994; 37: 313–320
- Kallunki P, Eddy R L, Byers M O, Kestila M, Shows T B, Tryggvason K. Cloning of human heparan sulfate proteoglycan core protein assignment of the gene (HSPG1) to Ip36.1 p35 and identification of a BamHI restriction fragment length polymorphism. Genomics 1991; 11: 389–396
- Cohen I R, Grassel S, Murdoch A D, Iozzo R V. Structural characterization of the complete human perlecan gene and its promoter. Proc Natl Acad Sci USA 1993; 90: 10404–10408
- Hansen P M, Chowdhury T, Deckert T, Hellgren A, Bain S C, Pociot F. Genetic variation of the heparan sulfate proteoglycan gene (perlecan gene): association with urinary albumin excretion in IDDM patients. Diabetes 1997; 46: 1658–1659
- Zatz R, Dunn R, Meyer T W, Anderson S, Rennke H, Brenner B M. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925–1930
- Anderson S, Brenner B M. Pathogenesis of diabetic glomerulopathy: hemodynamic considerations. Diabetes Metab Rev 1988; 4: 163–177
- Deckert T, Kofoed-Enevoldsen A, Vidal P, Norgaard K, Andreasen H B, Feldt-Rasmussen B. Size-and charge selectivity of glomerular filtration in type 1 (insulin-dependent) diabetic patients with and without albuminuria. Diabetologia 1993; 36: 244–251
- Tomlanovich S, Deen W M, Jones I HW, II, Schwartz H C, Myers B D. Functional nature of the glomerular injury in progressive diabetic glomerulopathy. Diabetes 1987; 36: 556–565
- Nakamura Y, Myers B D. Charge selectivity of proteinuria in diabetic glomerulopathy. Diabetes 1988; 37: 1202–1211
- Rosenzwig L J, Kanwar Y S. Removal of sulphated (heparan sulphate) or non sulphated (hyaluron acid) glycosaminoglycans results in increased permeability of the glomerular basement membrane to125I albumin. Lab Invest 1982; 47: 177–184
- Solini A, Vergnani L, Ricci F, Crepaldi G. Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care 1997; 20: 813–817
- van der Piji J W, van der Woude F J, Geelhoed-Duijvestijn P HLM, Frolich M, van der Meer F JM, Lemkes H HPJ, van ES L A. Danaparoid sodium lowers proteinuria in diabetic nephropathy. J Am Soc Nephrol 1997; 8: 456–462